Esophageal Cancer Clinical Trial
Official title:
A Multi-centre Real-world Non-interventional Observational Study to Compare Effectiveness and Safety of the Minimally Invasive Surgeries of Ivor-Lewis and Mckeown in Chinese Patients With IA-IIIB Esophageal Cancer
NCT number | NCT03428074 |
Other study ID # | 301-EC-01 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | December 1, 2017 |
Est. completion date | March 30, 2018 |
Verified date | May 2018 |
Source | Chinese PLA General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study was designed to compare effectiveness and safety of the surgeries of Ivor-Lewis and Mckeown in patients with esophageal cancer
Status | Completed |
Enrollment | 1862 |
Est. completion date | March 30, 2018 |
Est. primary completion date | March 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Pathologically diagnosed middle and lower thoracic IA-IIIB esophageal cancer after surgeries; - Patients who received minimally invasive radical dissections of Ivor-Lewis and Mckeown; - Patients who received tubular gastroesophageal reconstruction; Exclusion Criteria: - Patients complicated with arrhythmia, or serious disfunctions of heart, lung, liver, and kidney before surgeries; - Patients with second primary tumors; - Patients who received abdominal or thoracic surgeries; - Patients who received gastrostomy or nesteostomy before surgeries; - Patients with suspected cervical lymph metastases (in the subgroup of the patients who received the surgery of Mckeown) |
Country | Name | City | State |
---|---|---|---|
China | China-Japan Friendship Hospital | Beijing | Beijing |
China | Huaxi Hospital Affiliated to Sichuan University | Chengdu | Sichuan |
China | First Hospital Affiliated to Medical College, Zhejiang University | Hangzhou | Zhejiang |
China | Jiangsu Cancer Hospital | Nanjing | Jiangsu |
China | Shanghai Chest Hospital | Shanghai | Shanghai |
China | Tianjin Chest Hospital | Tianjin | Tianjin |
China | Tongji Hospital Affiliated to Huazhong Technology Hospital | Wuhan | Hubei |
China | Xi'an Tangdu Hospital | Xi'an | Shaanxi |
China | Henan cancer hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Chinese PLA General Hospital | LinkDoc Technology (Beijing) Co. Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of complications after surgeries | Incidence of complications after surgeries categorised by tumor biological characteristics | 2010 - 2017 | |
Other | Incision R0 rates | Incision R0 rates categorised by tumor biological characteristics | 2010 - 2017 | |
Other | Percentages of patients who received lymphadenectomy | Percentages of patients who received lymphadenectomy categorised by tumor biological characteristics | 2010 - 2017 | |
Other | Extents of lymph metastases | Extents of lymph metastases categorised by tumor biological characteristics | 2010 - 2017 | |
Primary | Overall survivals in patients with esophageal cancer who received surgeries | Overall survivals in patients with esophageal cancer who received surgeries categorised by tumor biological characteristics | 2010 - 2017 | |
Secondary | Death rates within 30 days after surgeries | Death rates within 30 days after surgeries categorised by tumor biological characteristics | 2010 - 2017 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 |